1. Qi, Xiao, Gao, Jing, Li, Zihao, Wang, Hongda, Tong, Ti. 2022. CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer. In Life sciences, 301, 120600. doi:10.1016/j.lfs.2022.120600. https://pubmed.ncbi.nlm.nih.gov/35504333/
2. Khan, Tashbib, Kryza, Thomas, Lyons, Nicholas J, He, Yaowu, Hooper, John D. 2021. The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention. In Cancer research, 81, 2259-2269. doi:10.1158/0008-5472.CAN-20-2978. https://pubmed.ncbi.nlm.nih.gov/33509939/
3. Wright, Heather J, Hou, Jue, Xu, Binzhi, Tromberg, Bruce J, Razorenova, Olga V. 2017. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. In Proceedings of the National Academy of Sciences of the United States of America, 114, E6556-E6565. doi:10.1073/pnas.1703791114. https://pubmed.ncbi.nlm.nih.gov/28739932/
4. Khan, Tashbib, Lyons, Nicholas J, Gough, Madeline, Hooper, John D, Kryza, Thomas. 2022. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy. In Theranostics, 12, 6915-6930. doi:10.7150/thno.78171. https://pubmed.ncbi.nlm.nih.gov/36276654/
5. Urabe, Fumihiko, Kosaka, Nobuyoshi, Yamamoto, Yusuke, Kimura, Takahiro, Ochiya, Takahiro. . Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein. In Journal of extracellular vesicles, 12, e12312. doi:10.1002/jev2.12312. https://pubmed.ncbi.nlm.nih.gov/36880252/
6. Huang, Hua, Pan, Yuwen, Mai, Qiuwen, Liu, Junxiu, Yao, Shuzhong. 2024. Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK/STAT signaling pathway. In Journal for immunotherapy of cancer, 12, . doi:10.1136/jitc-2024-009416. https://pubmed.ncbi.nlm.nih.gov/39455095/
7. Jia, Xi, Song, Erfei, Liu, Yan, Wang, Cunchuan, Xu, Aimin. 2023. Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese Chinese. In Cell reports. Medicine, 4, 101257. doi:10.1016/j.xcrm.2023.101257. https://pubmed.ncbi.nlm.nih.gov/37918406/
8. Alajati, Abdullah, D'Ambrosio, Mariantonietta, Troiani, Martina, De Bono, Johann, Alimonti, Andrea. . CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. In The Journal of clinical investigation, 130, 2435-2450. doi:10.1172/JCI131133. https://pubmed.ncbi.nlm.nih.gov/32250342/
9. Saponaro, Miriam, Flottmann, Sina, Eckstein, Markus, Hölzel, Michael, Alajati, Abdullah. 2023. CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression. In Scientific reports, 13, 73. doi:10.1038/s41598-022-26579-z. https://pubmed.ncbi.nlm.nih.gov/36593286/
智鼠故事 
